lanthanum polystyrene sulfonate powder
/ Liaoning Grand Nuokang Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 07, 2021
To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
(clinicaltrials.gov)
- P1/2; N=48; Recruiting; Sponsor: Liaoning Grand Nuokang Biopharmaceutical Co., Ltd.; Trial completion date: Apr 2022 ➔ Dec 2022; Trial primary completion date: Dec 2021 ➔ Jun 2022
Clinical • Trial completion date • Trial primary completion date • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease
October 29, 2020
To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
(clinicaltrials.gov)
- P1/2; N=48; Recruiting; Sponsor: Liaoning Grand Nuokang Biopharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting; Initiation date: Jul 2020 ➔ Oct 2020
Clinical • Enrollment open • Trial initiation date • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease
1 to 2
Of
2
Go to page
1